Movement Alert｜Innovent Biologics Falls 3.68% in Regular Trading, Biotechnology Sector Under Broad Selling Pressure

Market Focus06-22

On June 22, Innovent Biologics fell 3.68% in regular trading, trading at 72.5 HKD/share, with turnover of approximately 80.58 million HKD.

The decline was primarily driven by broad sector weakness across the biotechnology industry. Within the sector, AKESO fell 5.83%, SKB Bio fell 6.83%, Remegen fell 4.45%, 3SBio fell 4.5%, and BeiGene fell 3.3%, indicating systematic selling pressure rather than company-specific catalysts. Notably, the stock had previously rebounded to 78.75 HKD on June 15 following PCSK9 inhibitor approval and ADA conference data, and gained further on June 18 amid EULAR conference catalysts. The current pullback erases recent gains as broader market rotation toward AI and technology sectors continues to divert capital away from healthcare and biotech names. Separately, the company announced on the same day that its IBI3003 triple-specific antibody for multiple myeloma completed first patient dosing in a Phase III trial, though the positive pipeline development has not offset prevailing sector headwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1189194557?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 09:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189194557","market":"us","top_or_hot":-1,"title":"Movement Alert｜Innovent Biologics Falls 3.68% in Regular Trading, Biotechnology Sector Under Broad Selling Pressure","media":"Market Focus","content":"<p><p>On June 22, Innovent Biologics fell 3.68% in regular trading, trading at 72.5 HKD/share, with turnover of approximately 80.58 million HKD.</p><p>The decline was primarily driven by broad sector weakness across the biotechnology industry. Within the sector, AKESO fell 5.83%, SKB Bio fell 6.83%, Remegen fell 4.45%, 3SBio fell 4.5%, and BeiGene fell 3.3%, indicating systematic selling pressure rather than company-specific catalysts. Notably, the stock had previously rebounded to 78.75 HKD on June 15 following PCSK9 inhibitor approval and ADA conference data, and gained further on June 18 amid EULAR conference catalysts. The current pullback erases recent gains as broader market rotation toward AI and technology sectors continues to divert capital away from healthcare and biotech names. Separately, the company announced on the same day that its IBI3003 triple-specific antibody for multiple myeloma completed first patient dosing in a Phase III trial, though the positive pipeline development has not offset prevailing sector headwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Innovent Biologics Falls 3.68% in Regular Trading, Biotechnology Sector Under Broad Selling Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Innovent Biologics Falls 3.68% in Regular Trading, Biotechnology Sector Under Broad Selling Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-22 09:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 22, Innovent Biologics fell 3.68% in regular trading, trading at 72.5 HKD/share, with turnover of approximately 80.58 million HKD.</p><p>The decline was primarily driven by broad sector weakness across the biotechnology industry. Within the sector, AKESO fell 5.83%, SKB Bio fell 6.83%, Remegen fell 4.45%, 3SBio fell 4.5%, and BeiGene fell 3.3%, indicating systematic selling pressure rather than company-specific catalysts. Notably, the stock had previously rebounded to 78.75 HKD on June 15 following PCSK9 inhibitor approval and ADA conference data, and gained further on June 18 amid EULAR conference catalysts. The current pullback erases recent gains as broader market rotation toward AI and technology sectors continues to divert capital away from healthcare and biotech names. Separately, the company announced on the same day that its IBI3003 triple-specific antibody for multiple myeloma completed first patient dosing in a Phase III trial, though the positive pipeline development has not offset prevailing sector headwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1189194557","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189194557","pubTimestamp":1782092568,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 22, Innovent Biologics fell 3.68% in regular trading, trading at 72.5 HKD/share, with turnover of approximately 80.58 million HKD.The decline was primarily driven by broad sector weakness...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"动静快讯|信达生物常规交易跌3.68%生物科技板块遭广泛抛压","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On June 22, Innovent Biologics fell 3.68% in regular trading, trading at 72.5 HKD/share, with turnover of approximately 80.58 million HKD.The decline was primarily driven by broad sector weakness across the biotechnology industry. Within the sector, AKESO fell 5.83%, SKB Bio fell 6.83%, Remegen fell 4.45%, 3SBio fell 4.5%, and BeiGene fell 3.3%, indicating systematic selling pressure rather than company-specific catalysts. Notably, the stock had previously rebounded to 78.75 HKD on June 15 following PCSK9 inhibitor approval and ADA conference data, and gained further on June 18 amid EULAR conference catalysts. The current pullback erases recent gains as broader market rotation toward AI and technology sectors continues to divert capital away from healthcare and biotech names. Separately, the company announced on the same day that its IBI3003 triple-specific antibody for multiple myeloma completed first patient dosing in a Phase III trial, though the positive pipeline development has not offset prevailing sector headwinds.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1189194557","isCrawlerRequest":true}